ESR1 and breast cancer: Together these two endocrine treatment experiments indicate that these Nf1/Tp53-double-mutated tumors only partly depend on estrogen signaling and gain resistance quickly, closely mimicking the ER+/PR+/Ki67high human breast cancers that are resistant to endocrine therapy.